Dr Klaus Schollmeier has more than 30 years’ experience as a senior executive and advisor to the pharmaceutical and biotech industry, as well as in investment banking. Dr Schollmeier is currently CEO of KCS-GmbH, a consulting and investment company, and serves as non-executive chairman of several European Biotechnology companies. He was formerly CEO of SuppreMol GmbH, which was acquired by Baxter in 2015 for € 220 Mio. Before that, he led Santhera Pharmaceuticals AG as CEO since the company’s foundation in 2004, took the company public in 2006 and launched the first product in 2008. Prior to that, Dr. Schollmeier spent 16 years in the pharmaceutical industry at BASF, Knoll and Abbott. His scientific responsibilities included head of oncology/immunology research at BASF’s central laboratories in Germany, and senior director of biotechnology at BASF Bioresearch Corporation in Cambridge, US. His business functions included General Manager of BASF Pharma Netherlands and Vice President and General Manager for Western Europe. Dr Schollmeier holds a Ph.D. in Biology from the University of Düsseldorf, Germany.